|
AU2010247800A1
(en)
|
2009-05-11 |
2011-12-15 |
Berg Llc |
Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
|
|
WO2010135781A1
(en)
|
2009-05-27 |
2010-12-02 |
Immunaid Pty Ltd |
Methods of treating diseases
|
|
CN103299192B
(zh)
*
|
2010-09-21 |
2016-05-11 |
普罗蒂阿米克斯国际有限公司 |
与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记
|
|
ES2676205T3
(es)
*
|
2011-03-31 |
2018-07-17 |
Merck Sharp & Dohme Corp. |
Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
|
|
CA2832324C
(en)
|
2011-04-04 |
2022-03-15 |
Berg Llc |
Methods of treating central nervous system tumors
|
|
EP2634195B1
(en)
*
|
2012-03-01 |
2017-02-01 |
Miltenyi Biotec GmbH |
Separation of living untouched neurons
|
|
WO2013169693A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
EP2862111A4
(en)
*
|
2012-06-18 |
2016-01-20 |
Mayo Foundation |
DETERMINATION OF EFFICIENT TIMES FOR THE ADMINISTRATION OF CHEMOTHERAPY
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
SG10201903112WA
(en)
|
2013-04-08 |
2019-05-30 |
Berg Llc |
Treatment of cancer using coenzyme q10 combination therapies
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
KR102370843B1
(ko)
|
2013-09-04 |
2022-03-04 |
버그 엘엘씨 |
코엔자임 q10의 연속주입에 의한 암치료 방법
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
EP3099717B1
(en)
|
2014-01-31 |
2019-03-27 |
Novartis AG |
Antibody molecules to tim-3 and uses thereof
|
|
EP3114144A1
(en)
*
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
JP6991857B2
(ja)
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
EP3943101A1
(en)
|
2014-10-21 |
2022-01-26 |
SciClone Pharmaceuticals International Ltd. |
Treatment of cancer with immune stimulator alpha thymosin peptide
|
|
PT3212670T
(pt)
|
2014-10-29 |
2021-02-15 |
Bristol Myers Squibb Co |
Terapêutica de combinação para cancro
|
|
JP2016148623A
(ja)
*
|
2015-02-13 |
2016-08-18 |
京都府公立大学法人 |
大腸がんの検出方法
|
|
BR112017020952A2
(pt)
|
2015-04-13 |
2018-07-10 |
Five Prime Therapeutics Inc |
método de tratamento de câncer, composição e uso da composição
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
US10996217B2
(en)
*
|
2015-08-06 |
2021-05-04 |
Sekisui Medical Co., Ltd. |
Method for examining renal disease
|
|
KR102055396B1
(ko)
*
|
2015-08-11 |
2019-12-12 |
우시 바이올로직스 (케이만) 인코포레이티드 |
신규한 항-pd-1 항체
|
|
WO2017087576A1
(en)
|
2015-11-16 |
2017-05-26 |
Berg Llc |
Methods of treatment of temozolomide-resistant glioma using coenzyme q10
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
CN109310885B
(zh)
|
2016-03-15 |
2022-05-31 |
梅尔莎纳医疗公司 |
NaPi2b靶向抗体-药物缀合物及其使用方法
|
|
US20180021270A1
(en)
*
|
2016-07-21 |
2018-01-25 |
Berg Llc |
Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
|
|
US20190269666A1
(en)
*
|
2016-07-29 |
2019-09-05 |
Eli Lilly And Company |
Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
|
|
CA3041684C
(en)
|
2016-11-01 |
2023-09-26 |
Anaptysbio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
PT3565844T
(pt)
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體－藥物結合物之組合療法
|
|
CA3060935A1
(en)
|
2017-05-01 |
2018-11-08 |
The Children's Medical Center Coporation |
Methods and compositions relating to anti-pd1 antibody reagents
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
US12070489B2
(en)
|
2018-12-12 |
2024-08-27 |
Rappaport Family Institute For Research In The Medical Sciences |
Method of treating cancer with a cancer therapy in combination with another therapeutic agent
|
|
US12016900B2
(en)
|
2017-06-04 |
2024-06-25 |
Rappaport Family Institute For Research In The Medical Sciences |
Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
|
|
CA3066053A1
(en)
|
2017-06-04 |
2018-12-13 |
Rappaport Family Institute For Research In The Medical Sciences |
Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
|
|
SG11202001606XA
(en)
|
2017-09-13 |
2020-03-30 |
Five Prime Therapeutics Inc |
Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
|
|
WO2019055634A1
(en)
*
|
2017-09-13 |
2019-03-21 |
Mayo Foundation For Medical Education And Research |
IDENTIFICATION AND MONITORING OF A MACROPHAGE APOPTOSIS INHIBITOR
|
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
EP3727463A1
(en)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CN120714024A
(zh)
|
2018-06-20 |
2025-09-30 |
因赛特公司 |
抗pd-1抗体及其用途
|
|
KR102885113B1
(ko)
|
2018-10-18 |
2025-11-13 |
머크 샤프 앤드 돔 엘엘씨 |
항-rsv 항체의 제제 및 그의 사용 방법
|
|
AU2019369340A1
(en)
|
2018-10-29 |
2021-05-20 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
WO2020168244A1
(en)
|
2019-02-15 |
2020-08-20 |
Incelldx, Inc. |
Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
|
|
EP3966247B1
(en)
|
2019-05-06 |
2026-01-07 |
Brown University |
Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
CA3227993A1
(en)
|
2021-08-11 |
2023-02-16 |
OncoHost Ltd. |
Predicting patient response
|
|
WO2023236099A1
(en)
*
|
2022-06-08 |
2023-12-14 |
Zhejiang Shimai Pharmaceutical Co., Ltd. |
Antibodies against enpp3 and uses thereof
|
|
EP4650781A1
(en)
*
|
2023-01-10 |
2025-11-19 |
Toru Miyazaki |
Method for diagnosing cancer
|
|
WO2025034883A1
(en)
|
2023-08-08 |
2025-02-13 |
Quanta Therapeutics, Inc. |
Combination therapies with kras modulators
|
|
WO2025106905A1
(en)
|
2023-11-17 |
2025-05-22 |
Quanta Therapeutics, Inc. |
Combination therapies with a kras modulator and an immunomodulator inhibitor
|
|
WO2026060384A1
(en)
|
2024-09-16 |
2026-03-19 |
Quanta Therapeutics, Inc. |
Combination therapies with kras modulators
|